Across 92 Phase II/III bladder and urothelial cancer trials, site activity is highly concentrated in a small number of recurrent academic cancer centers. Hospital Universitari Vall d’Hebron is the clearest anchor site with 32 site-participation records, followed by Institut Gustave Roussy and Ospedale San Raffaele. Country-level allocation is led by Spain, France, Italy, and Germany, showing a Western/Southern Europe-heavy trial footprint.
The top 10 sites account for 178 site-participation records. Hospital Universitari Vall d’Hebron leads with 32 records, equal to 18.0% of the top-10 site-participation pool.
The site network is not evenly distributed. Repeated participation clusters around a small group of Spanish, French, Italian, and German referral centers with established genitourinary oncology and early-phase infrastructure.
Phase II trials represented 56 of 92 trials or 60.9%, while Phase III represented 36 of 92 trials or 39.1%. Most activity was authorized in 2024, with 69 of 92 trials or 75.0%.
The cohort is weighted toward Phase II and 2024 authorizations, indicating that much of the recent bladder/urothelial activity is still development-stage expansion rather than purely confirmatory Phase III execution.
The 10 largest country allocations account for 5,841 participant allocations. Spain leads with 1,492, followed by France with 996, Italy with 873, and Germany with 612.
Participant allocation follows the same pattern as site recurrence: Spain, France, Italy, and Germany carry the largest operational load, suggesting they are the main European geographies for bladder/urothelial trial deployment.
{"id":"1e9ce913-d242-47ee-966b-65eb1197e5f3","slug":"eu-bladder-urothelial-trial-active-sites","status":"published","title":"Which EU Sites are Most Active in Phase II/III Bladder and Urothelial Cancer Trials?","html":"\u003c!-- META DESCRIPTION:\nIn 92 Phase II/III bladder and urothelial cancer CTIS trials, EU activity is concentrated around Spanish, French, Italian, and German oncology networks. Vall d’Hebron leads the site ranking with 32 site-participation records, while Spain leads country-level participant allocation with 1,492 allocated participants.\n-->\n\n\u003cdiv style=\"background:#111315; color:#F2F2F2; font-family:Inter, ui-sans-serif, system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', sans-serif; padding:48px 24px 72px 24px;\">\n\u003cdiv style=\"max-width:768px; margin:0 auto;\">\n\n\u003csection style=\"background:linear-gradient(180deg,#122319 0%,#111315 100%); border:1px solid rgba(255,255,255,0.10); border-radius:8px; padding:32px; margin-bottom:64px;\">\n\n\u003cdiv style=\"font-size:12px; font-weight:650; color:#3FAE6F; text-transform:uppercase; letter-spacing:0.08em; margin-bottom:16px;\">\nClinical Trial Intelligence\n\u003c/div>\n\n\u003cdiv class=\"section-header-container\" data-export-section-header=\"true\" data-section-title=\"Which EU Sites Anchor Phase II/III Bladder and Urothelial Cancer Trials?\">\n\n\u003ch1 style=\"font-size:48px; line-height:56px; font-weight:650; letter-spacing:-0.035em; margin:0 0 12px 0; color:#F2F2F2;\">\nWhich EU Sites Anchor Phase II/III Bladder and Urothelial Cancer Trials?\n\u003c/h1>\n\n\u003cdiv style=\"font-size:13px; line-height:1.5; font-weight:600; color:#3FAE6F; margin:0 0 22px 0;\">\nJune 6, 2026\n\u003c/div>\n\n\u003cp style=\"font-size:17px; line-height:1.65; font-weight:400; color:rgba(255,255,255,0.70); margin:0 0 28px 0;\">\nAcross \u003cstrong style=\"font-weight:650; color:#F2F2F2;\">92 Phase II/III bladder and urothelial cancer trials\u003c/strong>, site activity is highly concentrated in a small number of recurrent academic cancer centers. Hospital Universitari Vall d’Hebron is the clearest anchor site with \u003cstrong style=\"font-weight:650; color:#F2F2F2;\">32 site-participation records\u003c/strong>, followed by Institut Gustave Roussy and Ospedale San Raffaele. Country-level allocation is led by Spain, France, Italy, and Germany, showing a Western/Southern Europe-heavy trial footprint.\n\u003c/p>\n\n\u003c/div>\n\n\u003cdiv style=\"display:grid; grid-template-columns:repeat(4,minmax(0,1fr)); gap:12px;\">\n\u003cdiv style=\"background:rgba(255,255,255,0.04); border:1px solid rgba(255,255,255,0.08); border-radius:8px; padding:16px;\">\n\u003cdiv style=\"font-size:12px; font-weight:650; color:rgba(255,255,255,0.55); text-transform:uppercase; letter-spacing:0.08em;\">Trials\u003c/div>\n\u003cdiv style=\"font-size:34px; line-height:40px; font-weight:650; color:#F2F2F2; margin-top:10px;\">92\u003c/div>\n\u003c/div>\n\u003cdiv style=\"background:rgba(255,255,255,0.04); border:1px solid rgba(255,255,255,0.08); border-radius:8px; padding:16px;\">\n\u003cdiv style=\"font-size:12px; font-weight:650; color:rgba(255,255,255,0.55); text-transform:uppercase; letter-spacing:0.08em;\">Phase II\u003c/div>\n\u003cdiv style=\"font-size:34px; line-height:40px; font-weight:650; color:#F2F2F2; margin-top:10px;\">56\u003c/div>\n\u003c/div>\n\u003cdiv style=\"background:rgba(255,255,255,0.04); border:1px solid rgba(255,255,255,0.08); border-radius:8px; padding:16px;\">\n\u003cdiv style=\"font-size:12px; font-weight:650; color:rgba(255,255,255,0.55); text-transform:uppercase; letter-spacing:0.08em;\">Phase III\u003c/div>\n\u003cdiv style=\"font-size:34px; line-height:40px; font-weight:650; color:#F2F2F2; margin-top:10px;\">36\u003c/div>\n\u003c/div>\n\u003cdiv style=\"background:rgba(255,255,255,0.04); border:1px solid rgba(255,255,255,0.08); border-radius:8px; padding:16px;\">\n\u003cdiv style=\"font-size:12px; font-weight:650; color:rgba(255,255,255,0.55); text-transform:uppercase; letter-spacing:0.08em;\">Top Site\u003c/div>\n\u003cdiv style=\"font-size:24px; line-height:30px; font-weight:650; color:#F2F2F2; margin-top:10px;\">Vall d’Hebron\u003c/div>\n\u003c/div>\n\u003c/div>\n\n\u003c/section>\n\n\u003cdiv style=\"height:1px; background:rgba(255,255,255,0.10); margin:0 0 64px 0;\">\u003c/div>\n\n\u003csection style=\"margin-bottom:64px;\">\n\u003cdiv class=\"section-header-container\" data-export-section-header=\"true\" data-section-title=\"Top 10 EU Site Anchors\">\n\n\u003ch2 style=\"font-size:30px; line-height:38px; font-weight:620; letter-spacing:-0.02em; color:#F2F2F2; margin:0 0 16px 0;\">\nTop 10 EU Site Anchors\n\u003c/h2>\n\n\u003cp style=\"font-size:17px; line-height:1.65; color:rgba(255,255,255,0.70); margin:0;\">\nThe top 10 sites account for \u003cstrong style=\"font-weight:650; color:#F2F2F2;\">178 site-participation records\u003c/strong>. Hospital Universitari Vall d’Hebron leads with \u003cstrong style=\"font-weight:650; color:#F2F2F2;\">32 records\u003c/strong>, equal to \u003cstrong style=\"font-weight:650; color:#F2F2F2;\">18.0%\u003c/strong> of the top-10 site-participation pool.\n\u003c/p>\n\u003c/div>\n\n\u003cdiv class=\"chart-container\" data-chart-title=\"Top EU Sites by Site-Participation Records\" data-export-chart=\"true\" style=\"background:#181B1E; border:1px solid rgba(255,255,255,0.10); border-radius:8px; padding:24px; margin-top:24px;\">\n\n\u003cdiv style=\"font-size:12px; font-weight:650; color:rgba(255,255,255,0.55); text-transform:uppercase; letter-spacing:0.08em; margin-bottom:18px;\">\nTop EU Sites by Site-Participation Records\n\u003c/div>\n\n\u003cdiv style=\"display:flex; flex-direction:column; gap:14px;\">\n\u003cdiv style=\"display:grid; grid-template-columns:260px 1fr 56px; gap:12px; align-items:center;\">\u003cdiv style=\"font-size:14px; color:#F2F2F2;\">Hospital Universitari Vall d’Hebron\u003c/div>\u003cdiv style=\"height:12px; background:rgba(255,255,255,0.08); border-radius:999px; overflow:hidden;\">\u003cdiv style=\"height:12px; width:100%; background:#3FAE6F;\">\u003c/div>\u003c/div>\u003cdiv style=\"font-size:14px; text-align:right;\">32\u003c/div>\u003c/div>\n\u003cdiv style=\"display:grid; grid-template-columns:260px 1fr 56px; gap:12px; align-items:center;\">\u003cdiv style=\"font-size:14px; color:#F2F2F2;\">Institut Gustave Roussy\u003c/div>\u003cdiv style=\"height:12px; background:rgba(255,255,255,0.08); border-radius:999px; overflow:hidden;\">\u003cdiv style=\"height:12px; width:72%; background:#3FAE6F;\">\u003c/div>\u003c/div>\u003cdiv style=\"font-size:14px; text-align:right;\">23\u003c/div>\u003c/div>\n\u003cdiv style=\"display:grid; grid-template-columns:260px 1fr 56px; gap:12px; align-items:center;\">\u003cdiv style=\"font-size:14px; color:#F2F2F2;\">Ospedale San Raffaele S.r.l.\u003c/div>\u003cdiv style=\"height:12px; background:rgba(255,255,255,0.08); border-radius:999px; overflow:hidden;\">\u003cdiv style=\"height:12px; width:53%; background:#3FAE6F;\">\u003c/div>\u003c/div>\u003cdiv style=\"font-size:14px; text-align:right;\">17\u003c/div>\u003c/div>\n\u003cdiv style=\"display:grid; grid-template-columns:260px 1fr 56px; gap:12px; align-items:center;\">\u003cdiv style=\"font-size:14px; color:#F2F2F2;\">MD Anderson Cancer Center Madrid\u003c/div>\u003cdiv style=\"height:12px; background:rgba(255,255,255,0.08); border-radius:999px; overflow:hidden;\">\u003cdiv style=\"height:12px; width:50%; background:#3FAE6F;\">\u003c/div>\u003c/div>\u003cdiv style=\"font-size:14px; text-align:right;\">16\u003c/div>\u003c/div>\n\u003cdiv style=\"display:grid; grid-template-columns:260px 1fr 56px; gap:12px; align-items:center;\">\u003cdiv style=\"font-size:14px; color:#F2F2F2;\">Hospital Universitario 12 de Octubre\u003c/div>\u003cdiv style=\"height:12px; background:rgba(255,255,255,0.08); border-radius:999px; overflow:hidden;\">\u003cdiv style=\"height:12px; width:47%; background:#3FAE6F;\">\u003c/div>\u003c/div>\u003cdiv style=\"font-size:14px; text-align:right;\">15\u003c/div>\u003c/div>\n\u003cdiv style=\"display:grid; grid-template-columns:260px 1fr 56px; gap:12px; align-items:center;\">\u003cdiv style=\"font-size:14px; color:#F2F2F2;\">Centre Leon Berard\u003c/div>\u003cdiv style=\"height:12px; background:rgba(255,255,255,0.08); border-radius:999px; overflow:hidden;\">\u003cdiv style=\"height:12px; width:44%; background:#3FAE6F;\">\u003c/div>\u003c/div>\u003cdiv style=\"font-size:14px; text-align:right;\">14\u003c/div>\u003c/div>\n\u003cdiv style=\"display:grid; grid-template-columns:260px 1fr 56px; gap:12px; align-items:center;\">\u003cdiv style=\"font-size:14px; color:#F2F2F2;\">Fondazione Policlinico Gemelli IRCCS\u003c/div>\u003cdiv style=\"height:12px; background:rgba(255,255,255,0.08); border-radius:999px; overflow:hidden;\">\u003cdiv style=\"height:12px; width:44%; background:#3FAE6F;\">\u003c/div>\u003c/div>\u003cdiv style=\"font-size:14px; text-align:right;\">14\u003c/div>\u003c/div>\n\u003cdiv style=\"display:grid; grid-template-columns:260px 1fr 56px; gap:12px; align-items:center;\">\u003cdiv style=\"font-size:14px; color:#F2F2F2;\">University Medical Center Hamburg-Eppendorf\u003c/div>\u003cdiv style=\"height:12px; background:rgba(255,255,255,0.08); border-radius:999px; overflow:hidden;\">\u003cdiv style=\"height:12px; width:41%; background:#3FAE6F;\">\u003c/div>\u003c/div>\u003cdiv style=\"font-size:14px; text-align:right;\">13\u003c/div>\u003c/div>\n\u003cdiv style=\"display:grid; grid-template-columns:260px 1fr 56px; gap:12px; align-items:center;\">\u003cdiv style=\"font-size:14px; color:#F2F2F2;\">Universitaetsklinikum Duesseldorf AöR\u003c/div>\u003cdiv style=\"height:12px; background:rgba(255,255,255,0.08); border-radius:999px; overflow:hidden;\">\u003cdiv style=\"height:12px; width:38%; background:#3FAE6F;\">\u003c/div>\u003c/div>\u003cdiv style=\"font-size:14px; text-align:right;\">12\u003c/div>\u003c/div>\n\u003cdiv style=\"display:grid; grid-template-columns:260px 1fr 56px; gap:12px; align-items:center;\">\u003cdiv style=\"font-size:14px; color:#F2F2F2;\">Assistance Publique Hopitaux de Paris\u003c/div>\u003cdiv style=\"height:12px; background:rgba(255,255,255,0.08); border-radius:999px; overflow:hidden;\">\u003cdiv style=\"height:12px; width:38%; background:#3FAE6F;\">\u003c/div>\u003c/div>\u003cdiv style=\"font-size:14px; text-align:right;\">12\u003c/div>\u003c/div>\n\u003c/div>\n\n\u003cdiv style=\"border-top:1px solid rgba(255,255,255,0.10); margin-top:20px; padding-top:10px; font-size:11px; color:rgba(255,255,255,0.45); letter-spacing:0.04em;\">\n\u003cspan>Site-participation records across Phase II/III bladder and urothelial cancer trials\u003c/span>\n\u003c/div>\n\u003c/div>\n\n\u003cdiv class=\"conclusion-container\" data-conclusion-title=\"Top EU Site Anchors\" data-export-conclusion=\"true\" style=\"border-left:3px solid #3FAE6F; background:rgba(63,174,111,0.08); border-radius:8px; padding:18px 20px; margin-top:24px;\">\n\u003cdiv style=\"font-size:12px; font-weight:650; color:#3FAE6F; text-transform:uppercase; letter-spacing:0.08em; margin-bottom:8px;\">Interpretation\u003c/div>\n\u003cp style=\"font-size:17px; line-height:1.65; color:rgba(255,255,255,0.78); margin:0;\">\nThe site network is not evenly distributed. Repeated participation clusters around a small group of Spanish, French, Italian, and German referral centers with established genitourinary oncology and early-phase infrastructure.\n\u003c/p>\n\u003c/div>\n\u003c/section>\n\n\u003cdiv style=\"height:1px; background:rgba(255,255,255,0.10); margin:0 0 64px 0;\">\u003c/div>\n\n\u003csection style=\"margin-bottom:64px;\">\n\u003cdiv class=\"section-header-container\" data-export-section-header=\"true\" data-section-title=\"Trial Volume by Phase and Year\">\n\n\u003ch2 style=\"font-size:30px; line-height:38px; font-weight:620; letter-spacing:-0.02em; color:#F2F2F2; margin:0 0 16px 0;\">\nTrial Volume by Phase and Year\n\u003c/h2>\n\n\u003cp style=\"font-size:17px; line-height:1.65; color:rgba(255,255,255,0.70); margin:0;\">\nPhase II trials represented \u003cstrong style=\"font-weight:650; color:#F2F2F2;\">56 of 92 trials\u003c/strong> or \u003cstrong style=\"font-weight:650; color:#F2F2F2;\">60.9%\u003c/strong>, while Phase III represented \u003cstrong style=\"font-weight:650; color:#F2F2F2;\">36 of 92 trials\u003c/strong> or \u003cstrong style=\"font-weight:650; color:#F2F2F2;\">39.1%\u003c/strong>. Most activity was authorized in 2024, with \u003cstrong style=\"font-weight:650; color:#F2F2F2;\">69 of 92 trials\u003c/strong> or \u003cstrong style=\"font-weight:650; color:#F2F2F2;\">75.0%\u003c/strong>.\n\u003c/p>\n\u003c/div>\n\n\u003cdiv class=\"chart-container\" data-chart-title=\"Trial Distribution by Year and Phase\" data-export-chart=\"true\" style=\"background:#181B1E; border:1px solid rgba(255,255,255,0.10); border-radius:8px; padding:24px; margin-top:24px;\">\n\u003cdiv style=\"font-size:12px; font-weight:650; color:rgba(255,255,255,0.55); text-transform:uppercase; letter-spacing:0.08em; margin-bottom:18px;\">\nTrial Distribution by Year and Phase\n\u003c/div>\n\n\u003cdiv style=\"display:grid; grid-template-columns:repeat(3,minmax(0,1fr)); gap:14px;\">\n\u003cdiv style=\"background:rgba(255,255,255,0.04); border:1px solid rgba(255,255,255,0.08); border-radius:8px; padding:16px;\">\n\u003cdiv style=\"font-size:14px; color:#F2F2F2; font-weight:650;\">2024\u003c/div>\n\u003cdiv style=\"font-size:32px; line-height:38px; font-weight:650; margin-top:10px;\">69\u003c/div>\n\u003cdiv style=\"font-size:13px; color:rgba(255,255,255,0.55); margin-top:6px;\">41 Phase II / 28 Phase III\u003c/div>\n\u003c/div>\n\u003cdiv style=\"background:rgba(255,255,255,0.04); border:1px solid rgba(255,255,255,0.08); border-radius:8px; padding:16px;\">\n\u003cdiv style=\"font-size:14px; color:#F2F2F2; font-weight:650;\">2025\u003c/div>\n\u003cdiv style=\"font-size:32px; line-height:38px; font-weight:650; margin-top:10px;\">18\u003c/div>\n\u003cdiv style=\"font-size:13px; color:rgba(255,255,255,0.55); margin-top:6px;\">12 Phase II / 6 Phase III\u003c/div>\n\u003c/div>\n\u003cdiv style=\"background:rgba(255,255,255,0.04); border:1px solid rgba(255,255,255,0.08); border-radius:8px; padding:16px;\">\n\u003cdiv style=\"font-size:14px; color:#F2F2F2; font-weight:650;\">2026\u003c/div>\n\u003cdiv style=\"font-size:32px; line-height:38px; font-weight:650; margin-top:10px;\">5\u003c/div>\n\u003cdiv style=\"font-size:13px; color:rgba(255,255,255,0.55); margin-top:6px;\">3 Phase II / 2 Phase III\u003c/div>\n\u003c/div>\n\u003c/div>\n\n\u003cdiv style=\"border-top:1px solid rgba(255,255,255,0.10); margin-top:20px; padding-top:10px; font-size:11px; color:rgba(255,255,255,0.45); letter-spacing:0.04em;\">\n\u003cspan>Trial counts by first CTIS authorization year\u003c/span>\n\u003c/div>\n\u003c/div>\n\n\u003cdiv class=\"conclusion-container\" data-conclusion-title=\"Trial Volume by Phase and Year\" data-export-conclusion=\"true\" style=\"border-left:3px solid #3FAE6F; background:rgba(63,174,111,0.08); border-radius:8px; padding:18px 20px; margin-top:24px;\">\n\u003cdiv style=\"font-size:12px; font-weight:650; color:#3FAE6F; text-transform:uppercase; letter-spacing:0.08em; margin-bottom:8px;\">Interpretation\u003c/div>\n\u003cp style=\"font-size:17px; line-height:1.65; color:rgba(255,255,255,0.78); margin:0;\">\nThe cohort is weighted toward Phase II and 2024 authorizations, indicating that much of the recent bladder/urothelial activity is still development-stage expansion rather than purely confirmatory Phase III execution.\n\u003c/p>\n\u003c/div>\n\u003c/section>\n\n\u003cdiv style=\"height:1px; background:rgba(255,255,255,0.10); margin:0 0 64px 0;\">\u003c/div>\n\n\u003csection style=\"margin-bottom:64px;\">\n\u003cdiv class=\"section-header-container\" data-export-section-header=\"true\" data-section-title=\"Country-Level Participant Allocation\">\n\n\u003ch2 style=\"font-size:30px; line-height:38px; font-weight:620; letter-spacing:-0.02em; color:#F2F2F2; margin:0 0 16px 0;\">\nCountry-Level Participant Allocation\n\u003c/h2>\n\n\u003cp style=\"font-size:17px; line-height:1.65; color:rgba(255,255,255,0.70); margin:0;\">\nThe 10 largest country allocations account for \u003cstrong style=\"font-weight:650; color:#F2F2F2;\">5,841 participant allocations\u003c/strong>. Spain leads with \u003cstrong style=\"font-weight:650; color:#F2F2F2;\">1,492\u003c/strong>, followed by France with \u003cstrong style=\"font-weight:650; color:#F2F2F2;\">996\u003c/strong>, Italy with \u003cstrong style=\"font-weight:650; color:#F2F2F2;\">873\u003c/strong>, and Germany with \u003cstrong style=\"font-weight:650; color:#F2F2F2;\">612\u003c/strong>.\n\u003c/p>\n\u003c/div>\n\n\u003cdiv class=\"chart-container\" data-chart-title=\"Top Country Participant Allocations\" data-export-chart=\"true\" style=\"background:#181B1E; border:1px solid rgba(255,255,255,0.10); border-radius:8px; padding:24px; margin-top:24px;\">\n\u003cdiv style=\"font-size:12px; font-weight:650; color:rgba(255,255,255,0.55); text-transform:uppercase; letter-spacing:0.08em; margin-bottom:18px;\">\nTop Country Participant Allocations\n\u003c/div>\n\n\u003cdiv style=\"display:flex; flex-direction:column; gap:14px;\">\n\u003cdiv style=\"display:grid; grid-template-columns:120px 1fr 70px; gap:12px; align-items:center;\">\u003cdiv>Spain\u003c/div>\u003cdiv style=\"height:12px; background:rgba(255,255,255,0.08); border-radius:999px; overflow:hidden;\">\u003cdiv style=\"height:12px; width:100%; background:#3FAE6F;\">\u003c/div>\u003c/div>\u003cdiv style=\"text-align:right;\">1,492\u003c/div>\u003c/div>\n\u003cdiv style=\"display:grid; grid-template-columns:120px 1fr 70px; gap:12px; align-items:center;\">\u003cdiv>France\u003c/div>\u003cdiv style=\"height:12px; background:rgba(255,255,255,0.08); border-radius:999px; overflow:hidden;\">\u003cdiv style=\"height:12px; width:67%; background:#3FAE6F;\">\u003c/div>\u003c/div>\u003cdiv style=\"text-align:right;\">996\u003c/div>\u003c/div>\n\u003cdiv style=\"display:grid; grid-template-columns:120px 1fr 70px; gap:12px; align-items:center;\">\u003cdiv>Italy\u003c/div>\u003cdiv style=\"height:12px; background:rgba(255,255,255,0.08); border-radius:999px; overflow:hidden;\">\u003cdiv style=\"height:12px; width:59%; background:#3FAE6F;\">\u003c/div>\u003c/div>\u003cdiv style=\"text-align:right;\">873\u003c/div>\u003c/div>\n\u003cdiv style=\"display:grid; grid-template-columns:120px 1fr 70px; gap:12px; align-items:center;\">\u003cdiv>Germany\u003c/div>\u003cdiv style=\"height:12px; background:rgba(255,255,255,0.08); border-radius:999px; overflow:hidden;\">\u003cdiv style=\"height:12px; width:41%; background:#3FAE6F;\">\u003c/div>\u003c/div>\u003cdiv style=\"text-align:right;\">612\u003c/div>\u003c/div>\n\u003cdiv style=\"display:grid; grid-template-columns:120px 1fr 70px; gap:12px; align-items:center;\">\u003cdiv>Poland\u003c/div>\u003cdiv style=\"height:12px; background:rgba(255,255,255,0.08); border-radius:999px; overflow:hidden;\">\u003cdiv style=\"height:12px; width:33%; background:#3FAE6F;\">\u003c/div>\u003c/div>\u003cdiv style=\"text-align:right;\">491\u003c/div>\u003c/div>\n\u003cdiv style=\"display:grid; grid-template-columns:120px 1fr 70px; gap:12px; align-items:center;\">\u003cdiv>Belgium\u003c/div>\u003cdiv style=\"height:12px; background:rgba(255,255,255,0.08); border-radius:999px; overflow:hidden;\">\u003cdiv style=\"height:12px; width:24%; background:#3FAE6F;\">\u003c/div>\u003c/div>\u003cdiv style=\"text-align:right;\">358\u003c/div>\u003c/div>\n\u003cdiv style=\"display:grid; grid-template-columns:120px 1fr 70px; gap:12px; align-items:center;\">\u003cdiv>Netherlands\u003c/div>\u003cdiv style=\"height:12px; background:rgba(255,255,255,0.08); border-radius:999px; overflow:hidden;\">\u003cdiv style=\"height:12px; width:22%; background:#3FAE6F;\">\u003c/div>\u003c/div>\u003cdiv style=\"text-align:right;\">322\u003c/div>\u003c/div>\n\u003cdiv style=\"display:grid; grid-template-columns:120px 1fr 70px; gap:12px; align-items:center;\">\u003cdiv>Denmark\u003c/div>\u003cdiv style=\"height:12px; background:rgba(255,255,255,0.08); border-radius:999px; overflow:hidden;\">\u003cdiv style=\"height:12px; width:19%; background:#3FAE6F;\">\u003c/div>\u003c/div>\u003cdiv style=\"text-align:right;\">276\u003c/div>\u003c/div>\n\u003cdiv style=\"display:grid; grid-template-columns:120px 1fr 70px; gap:12px; align-items:center;\">\u003cdiv>Czechia\u003c/div>\u003cdiv style=\"height:12px; background:rgba(255,255,255,0.08); border-radius:999px; overflow:hidden;\">\u003cdiv style=\"height:12px; width:16%; background:#3FAE6F;\">\u003c/div>\u003c/div>\u003cdiv style=\"text-align:right;\">234\u003c/div>\u003c/div>\n\u003cdiv style=\"display:grid; grid-template-columns:120px 1fr 70px; gap:12px; align-items:center;\">\u003cdiv>Portugal\u003c/div>\u003cdiv style=\"height:12px; background:rgba(255,255,255,0.08); border-radius:999px; overflow:hidden;\">\u003cdiv style=\"height:12px; width:13%; background:#3FAE6F;\">\u003c/div>\u003c/div>\u003cdiv style=\"text-align:right;\">187\u003c/div>\u003c/div>\n\u003c/div>\n\n\u003cdiv style=\"border-top:1px solid rgba(255,255,255,0.10); margin-top:20px; padding-top:10px; font-size:11px; color:rgba(255,255,255,0.45); letter-spacing:0.04em;\">\n\u003cspan>Summed participant allocations by country across country records\u003c/span>\n\u003c/div>\n\u003c/div>\n\n\u003cdiv class=\"conclusion-container\" data-conclusion-title=\"Country-Level Participant Allocation\" data-export-conclusion=\"true\" style=\"border-left:3px solid #3FAE6F; background:rgba(63,174,111,0.08); border-radius:8px; padding:18px 20px; margin-top:24px;\">\n\u003cdiv style=\"font-size:12px; font-weight:650; color:#3FAE6F; text-transform:uppercase; letter-spacing:0.08em; margin-bottom:8px;\">Interpretation\u003c/div>\n\u003cp style=\"font-size:17px; line-height:1.65; color:rgba(255,255,255,0.78); margin:0;\">\nParticipant allocation follows the same pattern as site recurrence: Spain, France, Italy, and Germany carry the largest operational load, suggesting they are the main European geographies for bladder/urothelial trial deployment.\n\u003c/p>\n\u003c/div>\n\u003c/section>\n\n\u003cdiv style=\"height:1px; background:rgba(255,255,255,0.10); margin:0 0 64px 0;\">\u003c/div>\n\n\u003csection style=\"margin-bottom:0;\">\n\u003cdiv class=\"section-header-container\" data-export-section-header=\"true\" data-section-title=\"Executive Interpretation\">\n\n\u003ch2 style=\"font-size:30px; line-height:38px; font-weight:620; letter-spacing:-0.02em; color:#F2F2F2; margin:0 0 16px 0;\">\nExecutive Interpretation\n\u003c/h2>\n\n\u003cp style=\"font-size:17px; line-height:1.","excerpt":"92 Phase II/III bladder/urothelial trials show Vall d’Hebron as top EU site with 32 records; Spain leads allocation with 1,492 participants.","coverImageUrl":null,"coverImageAlt":null,"author":null,"category":null,"tags":[],"metaTitle":"Which EU Sites are Most Active in Phase II/III Bladder and…","metaDescription":"92 Phase II/III bladder/urothelial trials show Vall d’Hebron as top EU site with 32 records; Spain leads allocation with 1,492 participants.","canonicalUrl":null,"robots":"index,follow","keywords":["bladder cancer","urothelial carcinoma","urothelial cancer","Phase II","Phase III","oncology trials","CTIS","EU clinical trial sites","Spain","France","Italy","Germany","Vall d’Hebron","Gustave Roussy","San Raffaele","MD Anderson Madrid","genitourinary oncology"],"ogTitle":"Which EU Sites are Most Active in Phase II/III Bladder and…","ogDescription":"92 Phase II/III bladder/urothelial trials show Vall d’Hebron as top EU site with 32 records; Spain leads allocation with 1,492 participants.","ogImageUrl":"https://trialagents.com/og-default.png","ogImageAlt":"Which EU Sites are Most Active in Phase II/III Bladder and Urothelial Cancer Trials?","ogType":"article","twitterCard":"summary_large_image","twitterTitle":"Which EU Sites are Most Active in Phase II/III Bladder and…","twitterDescription":"92 Phase II/III bladder/urothelial trials show Vall d’Hebron as top EU site with 32 records; Spain leads allocation with 1,492 participants.","twitterImageUrl":"https://trialagents.com/og-default.png","schemaJsonLd":{"@context":"https://schema.org","@graph":[{"@type":"Article","headline":"Which EU Sites are Most Active in Phase II/III Bladder and Urothelial Cancer Trials?","description":"92 Phase II/III bladder/urothelial trials show Vall d’Hebron as top EU site with 32 records; Spain leads allocation with 1,492 participants.","datePublished":"2026-06-06","dateModified":"2026-06-06","author":{"@type":"Organization","name":"TrialAgents","url":"https://trialagents.com"},"publisher":{"@type":"Organization","name":"TrialAgents","url":"https://trialagents.com"},"mainEntityOfPage":"https://trialagents.com/reports/eu-bladder-urothelial-trial-active-sites"},{"@type":"Dataset","name":"Which EU Sites are Most Active in Phase II/III Bladder and Urothelial Cancer Trials?","description":"92 Phase II/III bladder/urothelial trials show Vall d’Hebron as top EU site with 32 records; Spain leads allocation with 1,492 participants.","variableMeasured":["Top EU Sites by Site-Participation Records","Trial Distribution by Year and Phase","Top Country Participant Allocations"],"spatialCoverage":"Europe","isAccessibleForFree":true,"license":"https://creativecommons.org/licenses/by/4.0/","creator":{"@type":"Organization","name":"TrialAgents","url":"https://trialagents.com"}}]},"publishedAt":"2026-06-06T11:56:07.287Z","createdAt":"2026-06-06T11:56:08.036Z","updatedAt":"2026-06-06T11:56:08.036Z"}